Crisaborole

About Crisaborole (CAS 906673-24-3)

Crisaborole is a boron-containing small molecule used in research focused on inflammatory signaling, dermatology, and phosphodiesterase biology. In supplier catalogs and procurement records, it is frequently identified by CAS 906673-24-3 and 906673-24-3. Researchers also search crisaborole, crisaborole Pfizer, and Pfizer crisaborole when matching literature references with source documentation. Technical sources describe crisaborole structure as a benzoxaborole-derived scaffold with molecular formula C14H10BNO3 and molecular weight 251.05, which makes crisaborole chemical structure an important checkpoint during compound verification and screening preparation.

Application of Crisaborole

In research use, crisaborole is relevant for studies of inflammatory skin disease, PDE4 inhibition, cytokine modulation, and barrier-related biology. Because this molecule has an established connection to topical anti-inflammatory development, it is often selected for projects that compare non-steroidal modulators of inflammation or validate pathway activity in cell and tissue models. Scientists who review buy crisaborole, buy crisaborole online, crisaborole price, or crisaborole cost are usually not comparing supply alone - they are also checking whether the compound has the right documentation, traceable mechanism, and consistent catalog identity for translational research workflows.

In Vitro

In vitro, crisaborole is used to investigate phosphodiesterase-4 inhibition and the downstream consequences of elevated intracellular cAMP. This is important in models where cytokine regulation, inflammatory mediator release, and immune-cell signaling need to be studied with a defined small molecule. In this context, crisaborole structure and crisaborole chemical structure are not merely searchable descriptors - they help researchers confirm they are working with the expected boron-containing inhibitor before advancing to mechanistic assays or comparative studies.

In Vivo

In vivo interest in crisaborole is closely linked to inflammatory skin conditions, especially atopic dermatitis. Pfizer sources note that crisaborole acts as a PDE-4 inhibitor and that increased intracellular cAMP may reduce inflammatory cytokine signaling relevant to disease expression. This makes the compound useful in pharmacology and dermatology programs that need a recognized molecule for connecting target modulation with observable physiological outcomes. For teams screening sources before they buy crisaborole, this connection between mechanism and in vivo relevance is often a major part of the decision process.

Biochemical and Physiological Actions

Biochemically, crisaborole inhibits PDE-4 and thereby supports increased intracellular cAMP levels. Physiologically, this is associated with reduced production of selected pro-inflammatory cytokines involved in inflammatory skin responses. Guide to Pharmacology also notes that crisaborole acts primarily against the PDE4B isozyme, which adds further value for pathway-focused work where isoform relevance matters. These features explain why crisaborole structure appears repeatedly in technical searches and why crisaborole Pfizer remains a recognized reference in research and product documentation.

Features and Benefits of Crisaborole

• Well-defined identifiers, including CAS 906673-24-3, crisaborole structure, and crisaborole chemical structure
• Established PDE4-focused mechanism relevant for inflammation and dermatology studies
• Strong fit for researchers comparing Pfizer crisaborole with other anti-inflammatory reference molecules

For EBC-26322, crisaborole offers a useful combination of structural clarity, recognized biological activity, and strong relevance for modern inflammation research.